Arcellx Inc. is a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx Inc. is based in GAITHERSBURG, Md.
| Revenue (Most Recent Fiscal Year) | $107.94M |
| Net Income (Most Recent Fiscal Year) | $-107.35M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 139.41 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 10.89 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -602.73% |
| Net Margin (Trailing 12 Months) | -607.01% |
| Return on Equity (Trailing 12 Months) | -51.13% |
| Return on Assets (Trailing 12 Months) | -33.09% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.99 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.99 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.41 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.99 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.00 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.93 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 57.82M |
| Free Float | 52.99M |
| Market Capitalization | $5.00B |
| Average Volume (Last 20 Days) | 0.42M |
| Beta (Past 60 Months) | 0.31 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.35% |
| Percentage Held By Institutions (Latest 13F Reports) | 96.03% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |